Jobs
-
The FDA has announced the approval of Noctiva desmopressin acetate nasal spray for the treatment of nocturnal polyuria (overproduction of urine at night). Allergan licensed SER120 desmopressin nasal spray from Serenity Pharmaceuticals in 2010. In… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has announced the appointment of former MAP Pharmaceuticals President and CEO Timothy S. Nelson as Independent Director of the Board of Directors. Nelson led MAP Pharmaceuticals when it was acquired… Read more . . .
-
Copley Scientific has introduced a modified induction port fixture on its sample preparation unit (SPU) Model 2000, the company said. The modification allows for the use of a fluticasone propionate/salmeterol xinafoate (FP/SX) induction port in… Read more . . .
-
Lovelace Biomedical, a not-for-profit research organization which offers inhalation toxicology and other services for inhaled drug development, has announced the appointment of Larry Mallis as Director of Bioanalytical Operations. Mallis was most recently Director of… Read more . . .
-
GlaxoSmithKline has announced that a lung function study to demonstrate non-inferiority for once-daily use of the Relvar (Breo) Ellipta fluticasone furoate/vilanterol DPI compared to twice-daily Seretide (Advair) fluticasone propionate/salmeterol DPI in patients with well-controlled asthma… Read more . . .
-
According to Pharmaxis, treatment has been concluded in a Phase 3 trial of its Bronchitol mannitol DPI for the treatment of cystic fibrosis. A total of 423 patients in 21 countries were treated in the… Read more . . .
-
Adapt Pharma has filed a marketing authorization application in Europe for its naloxone nasal spray for the treatment of opioid overdose, the company said. Adapt’s naloxone nasal spray, marketed as Narcan, has been approved in… Read more . . .
-
For RDD Europe 2017, to be held April 25-28, 2017 at the Palais des Congrès in Antibes, France, organizers RDD Online and Aptar Pharma expect approximately 450 OINDP experts to attend the 3-day conference. Two… Read more . . .
-
Vectura met the £9 million calendar year royalty cap on GSK’s Ellipta DPI products in 2016, a year earlier than predicted, the company said. The £9 million calendar year royalty cap is included in a… Read more . . .
-
Dauntless Pharmaceuticals has initiated a Phase 1 clinical study of its DP1038 intranasal octreotide acetate, the company said. The study will compare DP1038 to Sandostatin octreotide acetate injection in healthy volunteers. DP1038 is in development… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA